argenx Meets Primary Endpoint in Phase II Celiac Disease Study

Argenx halted its Phase 3 UNITY trial of efgartigimod for Sjögren's disease after monitors found it unlikely to meet its primary goal. The decision, announced Oct. 8, was based on an interim analysis showing futility, not safety concerns. The drug remains approved for other conditions. Argenx plans to analyze the data and share findings. According to William Blair analysts, the trial included over 500 of 630 enrolled patients.

Morgan Stanley reduced its price target for Argenx (ARGX) to $1,140 from $1,250, maintaining an Overweight rating. The change follows the company's discontinuation of the Phase 3 UNITY study in Sjogren’s due to futility. The analyst views the updates as mixed for the indication but supportive of the broader investment thesis.

Argenx SE received a 'Buy' rating from DZ Bank and a 'Neutral' rating from Deutsche Bank. The stock has a 5-day change of +3.83%, a 1st Jan change of -10.23%, and a 2.12% increase at 08:55am. Ratings are based on various composite factors including valuation, EPS revisions, and visibility.

Argenx (ARGX) reported positive Phase 2 data for FB102 in celiac disease and halted its Phase 3 UNITY trial in Sjögren's disease. The stock has fallen 18.5% over 30 days, but long-term returns remain strong. Analysts debate its valuation, with some seeing it as slightly overvalued at €705.60, while a DCF model suggests significant undervaluation at €2,651.18.

H.C. Wainwright reiterated a Buy rating and $1,202 price target for argenx (ARGX) after positive Phase 2 trial results for FB102 in celiac disease. The stock is up 15% premarket. ARGX showed 70% revenue growth over the last year. Analysts have varied price targets and ratings for the company.

Argenx (ARGX) halted its Phase III UNITY trial of efgartigimod SC for Sjögren's disease after an IDMC recommended stopping due to futility. The study failed to meet its primary endpoint, though safety data was consistent. Shares fell 16% to €705.40.